Investigational Drug Information for Aleglitazar
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Aleglitazar?
Aleglitazar is an investigational drug.
There have been 22 clinical trials for Aleglitazar.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2012.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Coronary Disease. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].
Summary for Aleglitazar
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,055 |
| WIPO Patent Applications | 644 |
| Japanese Patent Applications | 170 |
| Clinical Trial Progress | Phase 3 (2012-11-01) |
| Vendors | 35 |
Recent Clinical Trials for Aleglitazar
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study) | Hoffmann-La Roche | Phase 3 |
| A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy | Hoffmann-La Roche | Phase 3 |
| A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy | Hoffmann-La Roche | Phase 3 |
Clinical Trial Summary for Aleglitazar
Top disease conditions for Aleglitazar
Top clinical trial sponsors for Aleglitazar
US Patents for Aleglitazar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
